stem cell transplants

Stem cell transplants, according to a study, may prolong disability in patients with active secondary progressive multiple sclerosis longer than some other medications.

According to an Italian study that was published in Neurology, the medical journal of the American Academy of Neurology, hematopoietic stem cell transplants may delay disability in individuals who have active secondary progressive MS.

79 people with active secondary progressive MS who received autologous hematopoietic stem cell transplants and 1,975 people who were treated with MS drugs from the Italian MS registry were included in the ten-year retrospective study.

Age, gender, and degree of disability were all comparable between the two groups. Alemtuzumab, azathioprine, glatiramer acetate, mitoxantrone, fingolimod, natalizumab, methotrexate, teriflunomide, cyclophosphamide, dimethyl fumarate, and beta-interferons were all included in the study.

The Expanded Disability Status Scale (EDSS) was used to assess each participant’s degree of disability.

Participants had a median score of 6.5 at the beginning of the study, which was defined as the requirement to constantly use a cane or brace on both sides to walk about 20 meters without stopping.

After five years of the study, the researchers discovered that, in contrast to the 46% of participants who took medications, 62% of those who received stem cell transplants experienced no worsening of their MS disability.

Also, 19% of people who had stem cell transplants had less disability five years later than they had at the beginning of the study, compared to just 4% of people who took medications.

Stem cell transplant recipients had a disability score that decreased by an average of 0.01 points per year over a ten-year period, indicating less disability. In contact, the average score for people who take medications went up by 0.16 points per year, which suggests that disability went up.

The study’s author, Dr. Matilde Inglese, from the University of Genoa in Italy, stated, “Our study shows that hematopoietic stem cell transplants were associated with a slowing of disability progression and a higher likelihood of disability improvement compared to other therapies.”

She went on to say, “While these results are encouraging, they are not applicable to patients with secondary progressive MS who do not have signs of inflammatory disease activity,” pointing out that additional research on larger groups of people is required to verify the findings.

LEAVE A REPLY

Please enter your comment!
Please enter your name here